Anke van den Berg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6651512/publications.pdf

Version: 2024-02-01

316 papers 13,489 citations

18482 62 h-index 101 g-index

327 all docs

327 docs citations

times ranked

327

17948 citing authors

#	Article	IF	CITATIONS
1	Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature. Clinical Lung Cancer, 2022, 23, e104-e115.	2.6	13
2	Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 667-675.	2.8	12
3	The Role of the MYC/miR-150/MYB/ZDHHC11 Network in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma. Genes, 2022, 13, 227.	2.4	3
4	Understanding the role of long-acting muscarinic antagonists in asthma treatment. Annals of Allergy, Asthma and Immunology, 2022, 128, 352-360.	1.0	7
5	CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2. Oncolmmunology, 2022, 11, 2033433.	4.6	9
6	Killer Cell Immunoglobulin-Like Receptor Haplotype B Modulates Susceptibility to EBV-Associated Classic Hodgkin Lymphoma. Frontiers in Immunology, 2022, 13, 829943.	4.8	4
7	Alpine altitude climate treatment for severe and uncontrolled asthma: An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1991-2024.	5.7	21
8	The Microbiome in Bronchial Biopsies from Smokers and Ex-Smokers with Stable COPD - A Metatranscriptomic Approach. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2022, 19, 81-87.	1.6	1
9	Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren's Syndrome. Cancers, 2022, 14, 1010.	3.7	5
10	The relation between age and airway epithelial barrier function. Respiratory Research, 2022, 23, 43.	3.6	13
11	Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma. Blood Cancer Journal, 2022, 12, 36.	6.2	8
12	Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma. Cancers, 2022, 14, 1346.	3.7	1
13	Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach. Cancers, 2022, 14, 1857.	3.7	6
14	Airway Wall Splice-QTL Analysis Reveals Novel Downstream Mechanisms for Well-Known GWAS Asthma-SNPs. , 2022, , .		0
15	Frequent 4EBP1 Amplification Induces Synthetic Dependence on FGFR Signaling in Cancer. Cancers, 2022, 14, 2397.	3.7	1
16	Prototype ORACLE Score Validation in NOVELTY: Predicted versus Observed Asthma Exacerbation Rates. , 2022, , .		0
17	Cytochrome P450 27C1 Level Dictates Lung Cancer Tumorigenicity and Sensitivity towards Multiple Anticancer Agents and Its Potential Interplay with the IGF-1R/Akt/p53 Signaling Pathway. International Journal of Molecular Sciences, 2022, 23, 7853.	4.1	4
18	Interaction between ERAP Alleles and HLA Class I Types Support a Role of Antigen Presentation in Hodgkin Lymphoma Development. Cancers, 2021, 13, 414.	3.7	6

#	Article	IF	CITATIONS
19	Soluble PD‣1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma. British Journal of Haematology, 2021, 193, 506-514.	2.5	9
20	Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC. Targeted Oncology, 2021, 16, 215-226.	3.6	7
21	Ultra-low-dose CT combined with noise reduction techniques for quantification of emphysema in COPD patients: An intra-individual comparison study with standard-dose CT. European Journal of Radiology, 2021, 138, 109646.	2.6	19
22	Frequent mutated <i>B2M</i> , <i>EZH2</i> , <i>IRF8</i> , and <i>TNFRSF14</i> in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. Blood Advances, 2021, 5, 3760-3775.	5.2	11
23	HLA Expression in Relation to HLA Type in Classic Hodgkin Lymphoma Patients. Cancers, 2021, 13, 5833.	3.7	1
24	Low Mutational Burden of Extra Nodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren's Syndrome. Blood, 2021, 138, 1331-1331.	1.4	1
25	Responsivity and Reproducibility of Sputum Inflammatory Biomarkers During COPD Exacerbation and Stable Phases – A Pilot Study. International Journal of COPD, 2021, Volume 16, 3055-3064.	2.3	1
26	Genetic Modification Approaches for Parasporins Bacillus thuringiensis Proteins with Anticancer Activity. Molecules, 2021, 26, 7476.	3.8	1
27	Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma. Cancer Treatment Reviews, 2020, 82, 101931.	7.7	33
28	Analysis of Released Circulating Tumor Cells During Surgery for Non-Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 1656-1666.	7.0	33
29	An All-In-One Transcriptome-Based Assay to Identify Therapy-Guiding Genomic Aberrations in Nonsmall Cell Lung Cancer Patients. Cancers, 2020, 12, 2843.	3.7	6
30	Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58. Blood, 2020, 136, 2437-2441.	1.4	28
31	MiR-378a-3p Is Critical for Burkitt Lymphoma Cell Growth. Cancers, 2020, 12, 3546.	3.7	12
32	MicroRNA Profiling in Bronchial Biopsies of Asthma Patients. , 2020, , .		0
33	Molecular imaging in lymphoma beyond 18F-FDG-PET: understanding the biology and its implications for diagnostics and therapy. Lancet Haematology,the, 2020, 7, e479-e489.	4.6	14
34	Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation. Lung Cancer, 2020, 146, 358-361.	2.0	37
35	The miR-26b-5p/KPNA2 Axis Is an Important Regulator of Burkitt Lymphoma Cell Growth. Cancers, 2020, 12, 1464.	3.7	19
36	Non-Coding RNAs in Cancer Radiosensitivity: MicroRNAs and IncRNAs as Regulators of Radiation-Induced Signaling Pathways. Cancers, 2020, 12, 1662.	3.7	44

#	Article	IF	CITATIONS
37	WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma. Therapeutic Advances in Hematology, 2020, 11, 204062071989837.	2.5	12
38	Interim thymus and activation regulated chemokine versus interim 18 Fâ€fluorodeoxyglucose positronâ€emission tomography in classical Hodgkin lymphoma response evaluation. British Journal of Haematology, 2020, 190, 40-44.	2.5	15
39	Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial. Haematologica, 2020, 105, 2805-2812.	3.5	30
40	Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non–Small-Cell Lung Cancer With Rare or Complex Mutational Profiles. JCO Precision Oncology, 2020, 4, 393-410.	3.0	32
41	Cell-free DNA as biomarker in Hodgkin lymphoma patients. Klinische Padiatrie, 2020, 232, .	0.6	o
42	Microenvironment, Cross-Talk, and Immune Escape Mechanisms. Hematologic Malignancies, 2020, , 69-86.	0.2	1
43	Cellular Senescence in Lung Fibroblasts from COPD Patients Is Associated with Altered Extracellular Matrix Regulation. , 2019, , .		0
44	Long Non-coding RNAs in the Development and Maintenance of Lymphoid Malignancies., 2019, , 127-149.		0
45	A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas. PLoS ONE, 2019, 14, e0223260.	2.5	4
46	WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage. Cancers, 2019, 11, 1743.	3.7	12
47	Current Smoking is Associated with Decreased Expression of miR-335-5p in Parenchymal Lung Fibroblasts. International Journal of Molecular Sciences, 2019, 20, 5176.	4.1	15
48	Targeted sequencing of circulating cell-free DNA in stage II-III resectable oesophageal squamous cell carcinoma patients. BMC Cancer, 2019, 19, 818.	2.6	16
49	Increased miR-142-3p Expression Might Explain Reduced Regulatory T Cell Function in Granulomatosis With Polyangiitis. Frontiers in Immunology, 2019, 10, 2170.	4.8	18
50	Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements. European Radiology, 2019, 29, 6018-6028.	4.5	6
51	Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 673-680.	2.8	24
52	Age-related gene and miRNA expression changes in airways of healthy individuals. Scientific Reports, 2019, 9, 3765.	3.3	34
53	CX Chemokine Receptor 7 Contributes to Survival of KRAS-Mutant Non-Small Cell Lung Cancer upon Loss of Epidermal Growth Factor Receptor. Cancers, 2019, 11, 455.	3.7	18
54	NGS-Based High-Throughput Screen to Identify MicroRNAs Regulating Growth of B-Cell Lymphoma. Methods in Molecular Biology, 2019, 1956, 269-282.	0.9	3

#	Article	IF	CITATIONS
55	Small Airways Disease Parameters Defined by PExA Particle Mass in Asthma, Asthma Remission and Healthy Controls. , 2019, , .		O
56	Marked TGF- \hat{l}^2 -regulated miRNA expression changes in both COPD and control lung fibroblasts. Scientific Reports, 2019, 9, 18214.	3.3	16
57	Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma. International Journal of Molecular Sciences, 2019, 20, 6036.	4.1	13
58	Intricate crosstalk between <scp>MYC</scp> and nonâ€coding <scp>RNA</scp> s regulates hallmarks of cancer. Molecular Oncology, 2019, 13, 26-45.	4.6	45
59	Argonaute 2 RNA Immunoprecipitation Reveals Distinct miRNA Targetomes of Primary Burkitt Lymphoma Tumors and Normal B Cells. American Journal of Pathology, 2018, 188, 1289-1299.	3.8	7
60	Effects of fluticasone propionate and budesonide on the expression of immune defense genes in bronchial epithelial cells. Pulmonary Pharmacology and Therapeutics, 2018, 50, 47-56.	2.6	19
61	Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma. Annals of Hematology, 2018, 97, 905-907.	1.8	3
62	Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform. Melanoma Research, 2018, 28, 96-104.	1.2	41
63	Targeting the Microenvironment in Hodgkin Lymphoma: Opportunities and Challenges. Molecular Pathology Library, 2018, , 59-90.	0.1	0
64	Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma. Cell Reports, 2018, 22, 3206-3216.	6.4	19
65	Combined loss of <scp>HLA</scp> I and <scp>HLA II</scp> expression is more common in the nonâ€ <scp>GCB</scp> type of diffuse large B cell lymphoma. Histopathology, 2018, 72, 886-888.	2.9	4
66	Circulating miRNAs in patients with Barrett's esophagus, high-grade dysplasia and esophageal adenocarcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 1150-1156.	1.4	11
67	KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC. Journal of Thoracic Oncology, 2018, 13, e249-e251.	1.1	28
68	Differential miRNA Expression Profiles in Cumulus and Mural Granulosa Cells from Human Pre-ovulatory Follicles. MicroRNA (Shariqah, United Arab Emirates), 2018, 8, 61-67.	1.2	23
69	Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma. Cancers, 2018, 10, 459.	3.7	16
70	Tuberous sclerosis complex is required for tumor maintenance in MYCâ€driven Burkitt's lymphoma. EMBO Journal, 2018, 37, .	7.8	10
71	MicroRNA High Throughput Loss-of-Function Screening Reveals an Oncogenic Role for miR-21-5p in Hodgkin Lymphoma. Cellular Physiology and Biochemistry, 2018, 49, 144-159.	1.6	20
72	Serum periostin does not reflect type 2-driven inflammation in COPD. Respiratory Research, 2018, 19, 112.	3.6	8

#	Article	IF	Citations
73	Novel genes and insights in complete asthma remission: A genomeâ€wide association study on clinical and complete asthma remission. Clinical and Experimental Allergy, 2018, 48, 1286-1296.	2.9	17
74	MBRS-36. IDENTIFICATION OF TWO PROTEIN-SIGNALING STATES DELINEATING TRANSCRIPTIONALLY HETEROGENEOUS HUMAN MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i136-i136.	1.2	0
75	Impact of acute exposure to cigarette smoke on airway gene expression. Physiological Genomics, 2018, 50, 705-713.	2.3	24
76	Involvement of MicroRNAs in the Aging-Related Decline of CD28 Expression by Human T Cells. Frontiers in Immunology, 2018, 9, 1400.	4.8	13
77	Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers. Cancers, 2018, 10, 10.	3.7	39
78	The Microenvironment in Epstein–Barr Virus-Associated Malignancies. Pathogens, 2018, 7, 40.	2.8	40
79	Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach. PLoS ONE, 2018, 13, e0193098.	2.5	20
80	OP0316 Increased expression of microrna-142–3p is associated with the functional defect of regulatory t cells in anti-neutrophil cytoplasmic antibody associated vasculitis. , 2018, , .		0
81	Mutation patterns in small cell and non-small cell lung cancer patients suggest a different level of heterogeneity between primary and metastatic tumors. Carcinogenesis, 2017, 38, bgw128.	2.8	29
82	Argonaute 2 immunoprecipitation revealed large tumor suppressor kinase 1 as a novel proapoptotic target of miR \hat{a} \in 21 in T cells. FEBS Journal, 2017, 284, 555-567.	4.7	7
83	Latrophilin receptors: novel bronchodilator targets in asthma. Thorax, 2017, 72, 74-82.	5.6	12
84	Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 4251-4258.	7.0	62
85	miR-24-3p Is Overexpressed in Hodgkin Lymphoma and Protects Hodgkin and Reed-Sternberg Cells from Apoptosis. American Journal of Pathology, 2017, 187, 1343-1355.	3.8	46
86	Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small-cell lung cancer patient. Annals of Oncology, 2017, 28, 1668-1670.	1.2	19
87	HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?. Oncolmmunology, 2017, 6, e1295202.	4.6	84
88	ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma. Leukemia, 2017, 31, 1470-1473.	7.2	39
89	Emerging roles for long noncoding RNAs in B-cell development and malignancy. Critical Reviews in Oncology/Hematology, 2017, 120, 77-85.	4.4	37
90	Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA. Journal of Nutrition, Health and Aging, 2017, 21, 92-104.	3.3	47

#	Article	IF	Citations
91	<i><i><scp>PTTG</scp>1<scp>IP</scp></i> and <i><scp>MAML</scp>3</i> , novel genomewide association study genes for severity of hyperresponsiveness in adult asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 792-801.</i>	5.7	12
92	All-in-one RNA-based assay to detect therapeutic biomarkers in lung cancer. Annals of Oncology, 2017, 28, vii10.	1.2	0
93	Lymphadenopathy driven by TCR-VÎ 3 8VÎ $^\prime$ 1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome. Blood Advances, 2017, 1, 1101-1106.	5.2	3
94	MicroRNA profiling of human primary macrophages exposed to dengue virus identifies miRNA-3614-5p as antiviral and regulator of ADAR1 expression. PLoS Neglected Tropical Diseases, 2017, 11, e0005981.	3.0	43
95	Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. Journal of Clinical Oncology, 2017, 35, 3722-3733.	1.6	48
96	HLA expression and HLA type associations in relation to EBV status in Hispanic Hodgkin lymphoma patients. PLoS ONE, 2017, 12, e0174457.	2.5	7
97	Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression. PLoS ONE, 2017, 12, e0182885.	2.5	21
98	Identification of transforming growth factor-beta-regulated microRNAs and the microRNA-targetomes in primary lung fibroblasts. PLoS ONE, 2017, 12, e0183815.	2.5	34
99	Abstract 754: Treatment decision-making of rareERBB2(HER2) mutations in lung cancer; a role for multidisciplinary molecular tumor boards. , 2017, , .		0
100	Abstract 2718: Molecular Tumor Board treatment predictions on rareEGFRexon 20 mutations. , 2017, , .		1
101	Abstract 2785: A comprehensive RNA-based assay for treatment prediction in non-small cell lung cancer patients. , 2017, , .		0
102	Target gene identification of TGF- \hat{l}^2 -induced miR-455-3p and miR-21-3p in lung fibroblasts. , 2017, , .		0
103	Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma. International Journal of Molecular Sciences, 2016, 17, 2127.	4.1	23
104	Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0152317.	2.5	10
105	Small RNA sequencing reveals a comprehensive miRNA signature of <i>BRCA1 < /i>-associated high-grade serous ovarian cancer. Journal of Clinical Pathology, 2016, 69, 979-985.</i>	2.0	11
106	Analysis of serum immune markers in seropositive and seronegative rheumatoid arthritis and in high-risk seropositive arthralgia patients. Scientific Reports, 2016, 6, 26021.	3.3	44
107	Meta-analysis of genome-wide association studies reveals genetic overlap between Hodgkin lymphoma and multiple sclerosis. International Journal of Epidemiology, 2016, 45, 728-740.	1.9	20
108	The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein–Barr virus presence and location within the tumor. Blood Cancer Journal, 2016, 6, e417-e417.	6.2	29

#	Article	IF	Citations
109	Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of <scp>sG</scp> alectinâ€1, <scp>sCD</scp> 163 and <scp>sCD</scp> 30 with TARC. British Journal of Haematology, 2016, 175, 868-875.	2.5	44
110	CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse. Genes and Immunity, 2016, 17, 363-366.	4.1	39
111	Long Noncoding RNA Expression Profiling in Normal B-Cell Subsets and Hodgkin Lymphoma Reveals Hodgkin and Reed-Sternberg Cell–Specific Long Noncoding RNAs. American Journal of Pathology, 2016, 186, 2462-2472.	3.8	36
112	Combining genomewide association study and lung <scp>eQTL</scp> analysis provides evidence for novel genes associated with asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1712-1720.	5.7	47
113	Single-cell sequencing reveals karyotype heterogeneity in murine and human malignancies. Genome Biology, 2016, 17, 115.	8.8	178
114	Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma. Neoplasia, 2016, 18, 339-346.	5.3	23
115	Budesonide and fluticasone propionate differentially affect the airway epithelial barrier. Respiratory Research, 2016, 17, 2.	3.6	30
116	Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature. Critical Reviews in Oncology/Hematology, 2016, 100, 107-116.	4.4	92
117	The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208.	3.5	67
118	Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients. JCI Insight, 2016, 1, e89631.	5.0	121
119	A Novel Prognostic Model Based on Tumor Microenvironment Biology in Relapse Biopsies Predicts Post-Autologous Stem Cell Transplantation Outcomes in Classical Hodgkin Lymphoma. Blood, 2016, 128, 1093-1093.	1.4	12
120	Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas. PLoS ONE, 2016, 11, e0146624.	2.5	8
121	Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing. PLoS ONE, 2016, 11, e0153065.	2.5	18
122	Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma. Oncotarget, 2016, 7, 2391-2400.	1.8	43
123	SETD2: an epigenetic modifier with tumor suppressor functionality. Oncotarget, 2016, 7, 50719-50734.	1.8	136
124	CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma. Experimental Hematology and Oncology, 2015, 4, 27.	5.0	13
125	Rheumatoid Arthritis, Immunosenescence and the Hallmarks of Aging. Current Aging Science, 2015, 8, 131-146.	1.2	76
126	Microenvironment, Crosstalk, and Immune Escape Mechanisms. Hematologic Malignancies, 2015, , 65-78.	0.2	0

#	Article	IF	CITATIONS
127	A Novel Risk Locus at 6p21.3 for Epstein–Barr Virus-Positive Hodgkin Lymphoma. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1838-1843.	2.5	20
128	Pim1 kinase activity preserves airway epithelial integrity upon house dust mite exposure. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L1344-L1353.	2.9	10
129	GATA6 expression in Barrett's oesophagus and oesophageal adenocarcinoma. Digestive and Liver Disease, 2015, 47, 73-80.	0.9	13
130	SF Treg cells transcribing high levels of Bcl-2 and microRNA-21 demonstrate limited apoptosis in RA. Rheumatology, 2015, 54, 950-958.	1.9	29
131	Long noncoding RNAs as a novel component of the Myc transcriptional network. FASEB Journal, 2015, 29, 2338-2346.	0.5	67
132	Genomic aberrations guiding treatment of non-small cell lung cancer patients. Cancer Treatment Communications, 2015, 4, 23-33.	0.4	17
133	Immunoâ€miRs: critical regulators of Tâ€cell development, function and ageing. Immunology, 2015, 144, 1-10.	4.4	141
134	Mir-155 Enhances B-Cell Lymphoma Growth By Targeting TBRG1. Blood, 2015, 126, 4820-4820.	1.4	14
135	Age-Associated Differences in MiRNA Signatures Are Restricted to CD45RO Negative T Cells and Are Associated with Changes in the Cellular Composition, Activation and Cellular Ageing. PLoS ONE, 2015, 10, e0137556.	2.5	23
136	T-cell Activation Induces Dynamic Changes in miRNA Expression Patterns in CD4 and CD8 T-cell Subsets. MicroRNA (Shariqah, United Arab Emirates), 2015, 4, 117-122.	1.2	37
137	Abstract 4757: Whole exome sequencing reveals a distinct mutation pattern in metastatic small cell lung cancer compared to non-small cell lung cancer. , 2015, , .		1
138	Abstract 4245: Detection of fusion genes in lung cancer biopsies of crizotinib resistant patients., 2015,		0
139	Mutations in CD58 and Other Immune System Related Genes in Hodgkin Lymphoma. Blood, 2015, 126, 1439-1439.	1.4	0
140	Impact of Radiotherapy and Rituximab on Outcome of Stage I(E) Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 1503-1503.	1.4	0
141	The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing. Leukemia, 2014, 28, 2248-2251.	7.2	74
142	Genetic Associations in Classical Hodgkin Lymphoma: A Systematic Review and Insights into Susceptibility Mechanisms. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2737-2747.	2.5	52
143	The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component. Seminars in Cancer Biology, 2014, 24, 15-22.	9.6	102
144	Comprehensive analysis of miRNA expression in T-cell subsets of rheumatoid arthritis patients reveals defined signatures of naive and memory Tregs. Genes and Immunity, 2014, 15, 115-125.	4.1	111

#	Article	IF	CITATIONS
145	Aging disturbs the balance between effector and regulatory CD4+ T cells. Experimental Gerontology, 2014, 60, 190-196.	2.8	115
146	Toll-like receptors in the pathogenesis of human B cell malignancies. Journal of Hematology and Oncology, 2014, 7, 57.	17.0	54
147	Shifted T-cell polarisation after agricultural dust exposure in mice and men. Thorax, 2014, 69, 630-637.	5.6	24
148	A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus. Nature Communications, 2014, 5, 3856.	12.8	78
149	Embryological signaling pathways in Barrett's metaplasia development and malignant transformation; mechanisms and therapeutic opportunities. Critical Reviews in Oncology/Hematology, 2014, 92, 25-37.	4.4	13
150	Insulin-Like Growth Factor 1 Receptor Is a Prognostic Factor in Classical Hodgkin Lymphoma. PLoS ONE, 2014, 9, e87474.	2.5	22
151	Correlation of MicroRNA-16, MicroRNA-21 and MicroRNA-101 Expression with Cyclooxygenase-2 Expression and Angiogenic Factors in Cirrhotic and Noncirrhotic Human Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e95826.	2.5	10
152	GATA6 expression in Barrett's metaplasia development and malignant progression Journal of Clinical Oncology, 2014, 32, 26-26.	1.6	0
153	Meta-Analysis of Hodgkin Lymphoma and Asthma Genome-Wide Association Scans reveals common variants in GATA3. Blood, 2014, 124, 135-135.	1.4	1
154	The entire miR \hat{a} \in 200 seed family is strongly deregulated in clear cell renal cell cancer compared to the proximal tubular epithelial cells of the kidney. Genes Chromosomes and Cancer, 2013, 52, 165-173.	2.8	26
155	Treatment of the bronchial tree from beginning to end: targeting small airway inflammation in asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 16-26.	5 . 7	69
156	Studying MicroRNAs in Lymphoma. Methods in Molecular Biology, 2013, 971, 265-276.	0.9	17
157	PML Nuclear Bodies and SATB1 Are Associated with HLA Class I Expression in EBV+ Hodgkin Lymphoma. PLoS ONE, 2013, 8, e72930.	2.5	5
158	Long Non-Coding RNAs Are Commonly Deregulated In Hodgkin Lymphoma. Blood, 2013, 122, 628-628.	1.4	2
159	Dual Role of miR-21 in CD4+ T-Cells: Activation-Induced miR-21 Supports Survival of Memory T-Cells and Regulates CCR7 Expression in Naive T-Cells. PLoS ONE, 2013, 8, e76217.	2.5	61
160	Cellular Localization and Processing of Primary Transcripts of Exonic MicroRNAs. PLoS ONE, 2013, 8, e76647.	2.5	24
161	Long Non-Coding RNAs As Components Of The MYC Network In B Cell Lymphoma. Blood, 2013, 122, 1260-1260.	1.4	0
162	A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. Blood, 2013, 122, 626-626.	1.4	0

#	Article	IF	CITATIONS
163	Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood, 2012, 120, 3530-3540.	1.4	122
164	Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. Haematologica, 2012, 97, 410-415.	3.5	56
165	Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma. Haematologica, 2012, 97, 572-578.	3.5	29
166	Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Annals of Oncology, 2012, 23, 2937-2942.	1.2	191
167	Generation of miRNA sponge constructs. Methods, 2012, 58, 113-117.	3.8	95
168	Genome-Wide Association Study of Classical Hodgkin Lymphoma and Epstein–Barr Virus Status–Defined Subgroups. Journal of the National Cancer Institute, 2012, 104, 240-253.	6.3	141
169	Rapid Generation of MicroRNA Sponges for MicroRNA Inhibition. PLoS ONE, 2012, 7, e29275.	2.5	125
170	HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China. PLoS ONE, 2012, 7, e31865.	2.5	25
171	HLA Associations in Classical Hodgkin Lymphoma: EBV Status Matters. PLoS ONE, 2012, 7, e39986.	2.5	52
172	Expression, Prognostic Value and Function of IGF1R in Hodgkin Lymphoma Blood, 2012, 120, 2640-2640.	1.4	0
173	A chronic obstructive pulmonary disease related signature in squamous cell lung cancer. Lung Cancer, 2011, 72, 177-183.	2.0	26
174	Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups. Blood, 2011, 118, 5211-5217.	1.4	2
175	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature, 2011, 471, 377-381.	27.8	551
176	MiRâ€17/106b seed family regulates p21 in Hodgkin's lymphoma. Journal of Pathology, 2011, 225, 609-617.	4.5	35
177	Randomized, Placebo-Controlled Phase III Study of Docetaxel Plus Carboplatin With Celecoxib and Cyclooxygenase-2 Expression As a Biomarker for Patients With Advanced Non–Small-Cell Lung Cancer: The NVALT-4 Study. Journal of Clinical Oncology, 2011, 29, 4320-4326.	1.6	105
178	Microenvironment, Cross-Talk, and Immune Escape Mechanisms., 2011,, 49-61.		1
179	Epidemiology of Classical Hodgkin Lymphoma and Its Association with Epstein Barr Virus in Northern China. PLoS ONE, 2011, 6, e21152.	2.5	28
180	CSF1R Expression of Hodgkin Reed Sternberg Cells Is Associated with the Number of Macrophages in the Tumor Microenvironment and Is Correlated with Treatment Outcome. Blood, 2011, 118, 427-427.	1.4	0

#	Article	IF	Citations
181	CCR4 Expression in Hodgkin Lymphoma. Blood, 2011, 118, 2626-2626.	1.4	O
182	Differentially expressed micro-RNAs in clear cell renal cell carcinoma. Cancer Genetics and Cytogenetics, 2010, 203, 71.	1.0	0
183	Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphoma. American Journal of Hematology, 2010, 85, 539-541.	4.1	24
184	MiRNA profiling in B nonâ€Hodgkin lymphoma: a <i>MYC</i> â€related miRNA profile characterizes Burkitt lymphoma. British Journal of Haematology, 2010, 149, 896-899.	2.5	71
185	A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nature Genetics, 2010, 42, 1126-1130.	21.4	177
186	Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1531-1535.	5.7	31
187	MicroRNAs, macrocontrol: Regulation of miRNA processing. Rna, 2010, 16, 1087-1095.	3.5	229
188	Maternal smoking during pregnancy decreases Wnt signalling in neonatal mice. Thorax, 2010, 65, 553-554.	5.6	33
189	479 LIVER TRANSPLANTATION FOR ALPHA-1 ANTITRYPSIN DEFICIENCY: HEPATOCELLULAR CARCINOMA IS COMMON AND DETERIORATES SURVIVAL. Journal of Hepatology, 2010, 52, S193-S194.	3.7	0
190	Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. Journal of Clinical Investigation, 2010, 120, 3594-3605.	8.2	193
191	Mid-Treatment Plasma Levels of Thymus Activated and Regulated Chemokine (TARC) Predict Treatment Outcome In Classical Hodgkin Lymphoma Patients. Blood, 2010, 116, 748-748.	1.4	4
192	Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients. PLoS ONE, 2010, 5, e10865.	2.5	16
193	Expression of the c-Met Oncogene Correlates with Favorable Progression Free Survival In Classical Hodgkin Lymphoma. Blood, 2010, 116, 3880-3880.	1.4	0
194	HLA Class I and EBV Positive Classical Hodgkin Lymphoma In the Chinese Population. Blood, 2010, 116, 2688-2688.	1.4	0
195	Protective and Predisposing HLA Alleles In Dutch Classical Hodgkin Lymphoma Patients. Blood, 2010, 116, 749-749.	1.4	1
196	Management of Asthma with ICS and LABAs: Different treatment strategies. Clinical Medicine Therapeutics, 2009, 1, CMT.S2283.	0.1	2
197	Latent Epstein-Barr Virus Infection of Tumor Cells in Classical Hodgkin's Lymphoma Predicts Adverse Outcome in Older Adult Patients. Journal of Clinical Oncology, 2009, 27, 3815-3821.	1.6	83
198	A high throughput experimental approach to identify miRNA targets in human cells. Nucleic Acids Research, 2009, 37, e137-e137.	14.5	105

#	Article	IF	CITATIONS
199	Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer, 2009, 9, 163.	2.6	190
200	Current smokingâ€specific gene expression signature in normal bronchial epithelium is enhanced in squamous cell lung cancer. Journal of Pathology, 2009, 218, 182-191.	4.5	63
201	The role of female sex hormones in the development and severity of allergic and nonâ€allergic asthma. Clinical and Experimental Allergy, 2009, 39, 1477-1481.	2.9	48
202	miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Laboratory Investigation, 2009, 89, 708-716.	3.7	103
203	Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Modern Pathology, 2009, 22, 547-555.	5 . 5	78
204	Similar efficacy of ciclesonide versus prednisolone to treat asthma worsening after steroid tapering. Respiratory Medicine, 2009, 103, 1216-1223.	2.9	15
205	Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer, 2009, 66, 372-378.	2.0	57
206	Hodgkin Lymphoma Cell Lines Are Characterized by a Specific miRNA Expression Profile. Neoplasia, 2009, 11, 167-IN9.	5. 3	133
207	Composite Lymphoma: EBV-positive Classic Hodgkin Lymphoma and Peripheral T-cell Lymphoma. Applied Immunohistochemistry and Molecular Morphology, 2009, 17, 72-76.	1.2	15
208	Expression of CD1c, CD1d and Presence of Invariant NKT Cells in Hodgkin Lymphoma Blood, 2009, 114, 3659-3659.	1.4	0
209	The HGF/c-Met Signaling Pathway in Hodgkin Lymphoma Blood, 2009, 114, 1551-1551.	1.4	1
210	Serum TARC Levels Correspond with Tumor Load and Response to Chemotherapy in Classical Hodgkin Lymphoma Patients Blood, 2009, 114, 3663-3663.	1.4	0
211	miRNA analysis in Bâ€cell chronic lymphocytic leukaemia: proliferation centres characterized by low miRâ€150 and high <i>BIC</i> /miRâ€155 expression. Journal of Pathology, 2008, 215, 13-20.	4.5	109
212	The CD4+CD26â^ T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile. Laboratory Investigation, 2008, 88, 482-490.	3.7	62
213	HLAâ€C protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens, 2008, 71, 219-226.	1.0	76
214	Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. British Journal of Haematology, 2008, 140, 527-536.	2.5	110
215	Autoimmune lymphoproliferative syndrome in a patient with a new minimal deletion in the death domain of the FAS gene. Human Pathology, 2008, 39, 137-141.	2.0	7
216	Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood, 2008, 111, 2339-2346.	1.4	114

#	Article	IF	Citations
217	Brain Death Induces Inflammation in the Donor Intestine. Transplantation, 2008, 86, 148-154.	1.0	35
218	A High Throughput Experimental Approach to Identify miRNA Target Genes in Hodgkin Lymphoma Blood, 2008, 112, 1461-1461.	1.4	42
219	Hodgkin's lymphoma associated T-cells exhibit a transcription factor profile consistent with distinct lymphoid compartments. Journal of Clinical Pathology, 2007, 60, 1092-1097.	2.0	19
220	Differential expression and distribution of epithelial adhesion molecules in non-small cell lung cancer and normal bronchus. Journal of Clinical Pathology, 2007, 60, 608-614.	2.0	63
221	HLA Class II Expression by Hodgkin Reed-Sternberg Cells Is an Independent Prognostic Factor in Classical Hodgkin's Lymphoma. Journal of Clinical Oncology, 2007, 25, 3101-3108.	1.6	118
222	HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood, 2007, 110, 3310-3315.	1.4	131
223	Strongly enhanced IL-10 production using stable galectin-1 homodimers. Molecular Immunology, 2007, 44, 506-513.	2.2	93
224	Deletion of C-MYC in the spectrum of transformed follicular lymphoma grade 3B: reply. Human Pathology, 2007, 38, 192-193.	2.0	0
225	$5\hat{a}\in^2$ -UTRFASmutation pattern and frequency in nodal diffuse large B-cell lymphoma similar to normal germinal center B cells. Leukemia and Lymphoma, 2007, 48, 851-852.	1.3	1
226	Global correlation of genome and transcriptome changes in classical Hodgkin lymphoma. Hematological Oncology, 2007, 25, 21-29.	1.7	24
227	Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. Oncogene, 2007, 26, 3769-3776.	5.9	131
228	Microarray amplification bias: loss of 30% differentially expressed genes due to long probe $\hat{a} \in \text{``poly(A)-tail distances. BMC Genomics, 2007, 8, 277.}$	2.8	17
229	miRNA Expression Profile of B-SLL Consistent with Normal Memory B Cells:BIC/miR–155 Specific Location in Proliferation Center Blood, 2007, 110, 2081-2081.	1.4	0
230	RT-PCR and immunohistochemical evaluation of sentinel lymph nodes afterin vivomapping with Patent Blue V in colon cancer patients. Scandinavian Journal of Gastroenterology, 2006, 41, 1073-1078.	1.5	13
231	Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma?. Human Pathology, 2006, 37, 528-533.	2.0	65
232	BCL6 alternative breakpoint region break and homozygous deletion of 17q24 in the nodular lymphocyte predominance type of Hodgkin's lymphoma–derived cell line DEV. Human Pathology, 2006, 37, 675-683.	2.0	29
233	Cytokine gene expression profile distinguishes CD4+/CD57+ T cells of the nodular lymphocyte predominance type of Hodgkin's lymphoma from their tonsillar counterparts. Journal of Pathology, 2006, 208, 423-430.	4.5	41
234	Gene expression analysis of dendritic/Langerhans cells and Langerhans cell histiocytosis. Journal of Pathology, 2006, 209, 474-483.	4.5	27

#	Article	IF	CITATIONS
235	The role of microRNAs in normal hematopoiesis and hematopoietic malignancies. Leukemia, 2006, 20, 1931-1936.	7.2	92
236	Upregulation of ADAM19 in Chronic Allograft Nephropathy American Journal of Transplantation, 2006, 6, 1673-1681.	4.7	18
237	Lack of <i>BIC</i> and microRNA miRâ€155 expression in primary cases of Burkitt lymphoma. Genes Chromosomes and Cancer, 2006, 45, 147-153.	2.8	219
238	Array comparative genomic hybridization reveals a very high frequency of deletions of the long arm of chromosome 6 in testicular lymphoma. Genes Chromosomes and Cancer, 2006, 45, 976-981.	2.8	21
239	Cigarette Smoke–induced Emphysema. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 751-758.	5.6	279
240	The Human Leukocyte Antigen Class I Region Is Associated with EBV-Positive Hodgkin's Lymphoma: HLA-A and HLA Complex Group 9 Are Putative Candidate Genes. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 2280-2284.	2.5	36
241	Regulation of pri-miRNA BIC Transcription and Processing in Burkitt Lymphoma Blood, 2006, 108, 2380-2380.	1.4	0
242	Discovery of Biomarkers for Hodgkin Lymphoma Using Proteomics Technology Blood, 2006, 108, 2261-2261.	1.4	0
243	Protease activity of plasma hemopexin. Kidney International, 2005, 68, 603-610.	5. 2	63
244	High expression of calcium-binding proteins, S100A10, S100A11 and CALM2 in anaplastic large cell lymphoma. British Journal of Haematology, 2005, 131, 596-608.	2.5	35
245	Genetic susceptibility to Hodgkin's lymphoma associated with the human leukocyte antigen region. European Journal of Haematology, 2005, 75, 34-41.	2.2	44
246	Report: workshop on mediastinal grey zone lymphoma. European Journal of Haematology, 2005, 75, 45-52.	2.2	19
247	BCL6 alternative translocation breakpoint cluster region associated with follicular lymphoma grade 3B. Genes Chromosomes and Cancer, 2005, 44, 301-304.	2.8	31
248	TIMP-1 expression in anaplastic large cell lymphoma is usually restricted to macrophages and only seldom observed in tumour cells. Journal of Pathology, 2005, 206, 445-450.	4.5	7
249	BIC and miRâ€155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. Journal of Pathology, 2005, 207, 243-249.	4.5	640
250	High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma. Journal of Clinical Pathology, 2005, 58, 520-524.	2.0	20
251	P53 Mutation Analysis of Colorectal Liver Metastases: Relation to Actual Survival, Angiogenic Status, and p53 Overexpression. Clinical Cancer Research, 2005, 11, 4067-4073.	7.0	34
252	Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet, The, 2005, 365, 2216-2224.	13.7	155

#	Article	IF	CITATIONS
253	Expression of the T-Cell Transcription Factors, GATA-3 and T-bet, in the Neoplastic Cells of Hodgkin Lymphomas. American Journal of Pathology, 2005, 166, 127-134.	3.8	56
254	Brain death causes structural and inflammatory changes in donor intestine. Transplantation Proceedings, 2005, 37, 448-449.	0.6	24
255	Polymorphisms and Lack of or Aberrant Expression of HLA Class I and II May Influence Antigen Presentation in Classical Hodgkin Lymphoma Blood, 2005, 106, 20-20.	1.4	1
256	Haplotype-Based Sequencing To Delineate the Associated HLA Class I Region for EBV Positive Hodgkin Lymphoma Blood, 2005, 106, 971-971.	1.4	0
257	Lack of BIC and microRNA miR-155 Expression in Primary Cases of Burkitt Lymphoma Blood, 2005, 106, 1922-1922.	1.4	0
258	Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. British Journal of Cancer, 2004, 90, 2411-2417.	6.4	69
259	Enhanced ecto-apyrase activity of stimulated endothelial or mesangial cells is downregulated by glucocorticoids in vitro. European Journal of Pharmacology, 2004, 501, 191-198.	3.5	11
260	Dimeric galectin-1 induces IL-10 production in T-lymphocytes: an important tool in the regulation of the immune response. Journal of Pathology, 2004, 204, 511-518.	4.5	87
261	Development of Lymphoma in Autoimmune Lymphoproliferative Syndrome (ALPS) and its Relationship to Fas Gene Mutations. Leukemia and Lymphoma, 2004, 45, 423-431.	1.3	66
262	Prolonged survival of rat islet xenografts in mice after CD45RB monotherapy. Transplantation, 2004, 77, 386-391.	1.0	12
263	Immune Dysfunction in Classical Hodgkin's Lymphoma. , 2004, , 315-334.		2
264	High Expression of Micro-RNA BIC / miR155 in All Subtypes of Hodgkin Lymphoma Blood, 2004, 104, 430-430.	1.4	1
265	Serial Analysis of Gene Expression Revealed Consistent Downregulation of More Than 100 Genes in Hodgkin Lymphoma Blood, 2004, 104, 4288-4288.	1.4	0
266	Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 443, 164-169.	2.8	32
267	High expression of Bâ€cell receptor inducible gene <i>BIC</i> in all subtypes of Hodgkin lymphoma. Genes Chromosomes and Cancer, 2003, 37, 20-28.	2.8	224
268	Induction of glomerular alkaline phosphatase after challenge with lipopolysaccharide. International Journal of Experimental Pathology, 2003, 84, 135-144.	1.3	37
269	Production of hemopexin by TNF- \hat{l}_{\pm} stimulated human mesangial cells. Kidney International, 2003, 63, 1681-1686.	5.2	31
270	Splenic Marginal Zone Lymphomas Presenting with Splenomegaly and Typical Immunophenotype Are Characterized by Allelic Loss in 7q31-32. Modern Pathology, 2003, 16, 1210-1217.	5.5	41

#	Article	IF	Citations
271	Low Frequency of FAS Mutations in Reed-Sternberg Cells of Hodgkin's Lymphoma. American Journal of Pathology, 2003, 162, 29-35.	3.8	54
272	Identification of chromosomal copy number changes associated with transformation of follicular lymphoma to diffuse large B-cell lymphoma. Human Pathology, 2003, 34, 915-923.	2.0	28
273	FAS Gene Mutation in a Case of Autoimmune Lymphoproliferative Syndrome Type IA With Accumulation of $\hat{l}^3\hat{l}'+T$ Cells. American Journal of Surgical Pathology, 2003, 27, 546-553.	3.7	10
274	High expression of TIAF-1 in chronic kidney and liver allograft rejection and in activated T-helper cells1. Transplantation, 2003, 75, 2076-2082.	1.0	19
275	Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary $t(14;18)$, $3q27$, or other translocations: $t(14;18)$ and $3q27$ are mutually exclusive. Blood, 2003, 101, 1149-1154.	1.4	136
276	Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Annals of Oncology, 2002, 13, 52-56.	1.2	136
277	Germline FAS gene mutation in a case of ALPS and NLP Hodgkin lymphoma. Blood, 2002, 99, 1492-1494.	1.4	34
278	Clonal relation in a case of CLL, ALCL, and Hodgkin composite lymphoma. Blood, 2002, 100, 1425-1429.	1.4	79
279	Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical hodgkin lymphomas. International Journal of Cancer, 2002, 99, 665-672.	5.1	66
280	Analysis of <i>in Vivo</i> Endothelial Cell Activation Applying RTâ€PCR following Endothelial Cell Isolation by Laser Dissection Microscopy. Annals of the New York Academy of Sciences, 2002, 973, 586-589.	3.8	9
281	Clonal relation in a case of CLL, ALCL, and Hodgkin composite lymphoma. Blood, 2002, 100, 1425-9.	1.4	23
282	Hyaline vascular Castleman's disease: a case report and brief review of the literature. Netherlands Journal of Medicine, 2002, 60, 444-7.	0.5	7
283	TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus. International Journal of Cancer, 2001, 94, 60-66.	5.1	54
284	Frequent lack of translation of antigen presentation-associated molecules MHC class I, CD1a and ?2-microglobulin in Reed-Sternberg cells., 2000, 86, 548-552.		7
285	Interaction between host T cells and Reed–Sternberg cells in Hodgkin lymphomas. Seminars in Cancer Biology, 2000, 10, 345-350.	9.6	84
286	Seriai analysis of gene expression: rapid RT-PCR analysis of unknown SAGE tags. Nucleic Acids Research, 1999, 27, i-iii.	14.5	19
287	A comparison of genomic structures and expression patterns of two closely related flanking genes in a critical lung cancer region at 3p21.3. European Journal of Human Genetics, 1999, 7, 478-486.	2.8	45
288	High Expression of the CC Chemokine TARC in Reed-Sternberg Cells. American Journal of Pathology, 1999, 154, 1685-1691.	3.8	349

#	Article	IF	Citations
289	An Evolutionary Rearrangement of the Xp11.3–11.23 Region in 3p21.3, a Region Frequently Deleted in a Variety of Cancers. Genomics, 1999, 60, 238-240.	2.9	20
290	Pathogenesis and medical therapy of primary sclerosing cholangitis. Any news?. European Journal of Gastroenterology and Hepatology, 1999, 11, 121-124.	1.6	5
291	Immune reactions in classical Hodgkin's lymphoma. Seminars in Hematology, 1999, 36, 253-9.	3.4	45
292	Genetic analysis of 2 cases of clear cell renal cancer in 2 sisters. , 1998, 77, 494-497.		4
293	A cosmid and cDNA fine physical map of a human chromosome 13q14 region frequently lost in B-cell chronic lymphocytic leukemia and identification of a new putative tumor suppressor gene, Leu5. FEBS Letters, 1998, 426, 266-270.	2.8	59
294	An Alternative Route for Multistep Tumorigenesis in a Novel Case of Hereditary Renal Cell Cancer and a t(2;3)(q35;q21) Chromosome Translocation. American Journal of Human Genetics, 1998, 62, 1475-1483.	6.2	73
295	Involvement of multiple loci on chromosome 3 in renal cell cancer development., 1997, 19, 59-76.		69
296	NormalFHIT transcripts in renal cell cancer- and lung cancer-derived cell lines, including a cell line with a homozygous deletion in the FRA3B region., 1997, 19, 220-227.		38
297	Analysis of multiple renal cell adenomas and carcinomas suggests allelic loss at 3p21 to be a prerequisite for malignant development., 1997, 19, 228-232.		41
298	Genetics as a diagnostic tool in sarcomatoid renal-cell cancer. , 1997, 72, 265-269.		18
299	Involvement of multiple loci on chromosome 3 in renal cell cancer development. Genes Chromosomes and Cancer, 1997, 19, 59-76.	2.8	44
300	Isolation of the Human Semaphorin III/F Gene (SEMA3F) at Chromosome 3p21, a Region Deleted in Lung Cancer. Genomics, 1996, 32, 39-48.	2.9	134
301	Ordering of polymorphic markers in the chromosome region 3p21. Cytogenetic and Genome Research, 1996, 72, 225-228.	1.1	7
302	Chromosomal findings and p53-mutation analysis in chromophilic renal-cell carcinomas., 1996, 68, 47-50.		19
303	Major role for a 3p21 region and lack of involvement of the t(3;8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis., 1996, 15, 64-72.		52
304	Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2881-2884.	3.6	49
305	An 80 Kb P1 clone from chromosome 3p21.3 suppresses tumor growth in vivo. Oncogene, 1996, 13, 2387-96.	5.9	38
306	Defining the position of the breakpoint of the constitutional t(3;6) occurring in a family with renal cell carcinoma. Genes Chromosomes and Cancer, 1995, 12, 224-228.	2.8	14

#	Article	IF	CITATIONS
307	The genomic structure of the human UBE1L gene. Gene Expression, 1995, 4, 163-75.	1.2	15
308	Somatic mutations of the von Hippel $\hat{a}\in$ " Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Human Molecular Genetics, 1994, 3, 2169-2173.	2.9	341
309	A homozygous deletion in a small cell lung cancer cell line involving a 3p21 region with a marked instability in yeast artificial chromosomes. Cancer Research, 1994, 54, 4183-7.	0.9	66
310	A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin-activating enzyme Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 6071-6075.	7.1	91
311	A PCR-Aided Transcript Titration Assay Revealing Very Low Expression of a Gene at Band 3p21 in 33 Cell Lines Derived from all Types of Lung Cancer. European Journal of Human Genetics, 1993, 1, 156-163.	2.8	6
312	A gene from human chromosome region 3p21 with reduced expression in small cell lung cancer. Cancer Research, 1992, 52, 1536-41.	0.9	35
313	A new RFLP identified at the D3S48 locus. Nucleic Acids Research, 1991, 19, 4797-4797.	14.5	4
314	Partial 3q duplication syndrome and assignment of D3S5 to 3q25–3q28. Human Genetics, 1991, 87, 151-154.	3.8	38
315	131 Are chromosome 3 deletions a consistent abnormality in mesotheliomas?. Cancer Genetics and Cytogenetics, 1989, 38, 203.	1.0	2
316	Direct molecular analysis of a deletion of 3p in tumors from patients with sporadic renal cell carcinoma. Cancer Genetics and Cytogenetics, 1988, 32, 281-285.	1.0	33